HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.